Search hospitals > Illinois > Effingham
Crossroads Cancer Center
Claim this profileEffingham, Illinois 62401
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
357 reported clinical trials
3 medical researchers
Summary
Crossroads Cancer Center is a medical facility located in Effingham, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Crossroads Cancer Center is involved with conducting 357 clinical trials across 473 conditions. There are 3 research doctors associated with this hospital, such as Bryan A. Faller, James L. Wade, and Harold Yoon, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Bryan A. FallerCrossroads Cancer Center2 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
226 reported clinical trials
291 drugs studied
James L. WadeDecatur Memorial Hospital3 years of reported clinical research
Studies Recurrence
Studies Breast Cancer
11 reported clinical trials
20 drugs studied
Harold Yoon, MDDecatur Memorial Hospital5 years of reported clinical research
Studies Prostate Cancer
Studies Mouth Sore
2 reported clinical trials
5 drugs studied
Clinical Trials running at Crossroads Cancer Center
Breast Cancer
Prostate Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Gastric Cancer
Esophageal Cancer
Renal Cell Carcinoma
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Crossroads Cancer Center?
Crossroads Cancer Center is a medical facility located in Effingham, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Crossroads Cancer Center is involved with conducting 357 clinical trials across 473 conditions. There are 3 research doctors associated with this hospital, such as Bryan A. Faller, James L. Wade, and Harold Yoon, MD.
Where is Crossroads Cancer Center located?
Crossroads Cancer Center is located at 905 Medical Park Drive, Effingham, IL 62401, approximately 0.93 miles from downtown Effingham.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Crossroads Cancer Center, please refer to their official website for direct contact information. For additional support, Cancer Care Specialists of Illinois can be contacted at the following clinic numbers: Decatur Clinic - 217-876-6600, Effingham Clinic - 217-342-2066, Centralia Clinic - 618-436-5410, and O’Fallon Clinic - 618-416-7970.
What insurance does Crossroads Cancer Center accept?
The Crossroads Cancer Center accepts a wide range of insurance plans, including but not limited to Aetna Choice POS, Anthem PPO, BCBS Blue Card PPO, Cigna HMO, and United Healthcare AARP Secure Horizons HMO. They do not accept Medicare or Medicaid, with exceptions for specific plans such as United Healthcare AARP Secure Horizons HMO and Aetna Medicare Advantage PPO. For insurance plans not listed, contacting your insurance provider or the hospital directly is recommended to inquire about coverage.
What awards or recognition has Crossroads Cancer Center received?
Crossroads Cancer Center, affiliated with Cancer Care Specialists of Illinois, is renowned for its contributions to cancer research and care. It engages in research studies and clinical trials in partnership with prestigious organizations such as the National Cancer Institute and the American Society of Clinical Oncology. These efforts have garnered the center numerous accolades, solidifying its status as a top-tier cancer care provider.